Research Title: An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (RAVEN)

Sponsor: Novartis Pharmaceuticals

Principal Investigator: Robert Stoltz, M.D., Ph.D.

Description: Following a 4-week maximum screening period, patients will be randomized and treated for approximately 76 weeks. Treatment visits will be scheduled in 4-week intervals. After 6 initial monthly injections of brolucizumab or aflibercept (loading phase), subjects will enter a one-year individualized flexible treatment (IFT) phase. During the IFT phase, an assessment of disease stability will be performed at each monthly visit and subjects will receive either an active or a sham injection. Treatment with active will be interrupted when disease stability is reached. Maximum study duration per patient is 80 weeks.

Start Date: October 2019

Recruitment: Enrolling

Project Personnel: Leslie Marcus, CCRC; Caitlin Harrison, CCRC, COA; Stephanie Campbell, CRC, COA; Amber Adams, CRC, COA

Location(s): Marietta; 833 Campbell Hill Street, Suite 300, Marietta, GA 30060

Active Trials

Past Trials

What Our Patients Say

"I would first like to say, that it is a pleasure coming every month to get my eye injections solely based on the staff and my retina specialist! They are always so sweet, well educated, and very welcoming!"

- Hayley

"The staff is kind and very well informed. They walk you through exactly what is happening and give you all your options upfront (including financials). I would 100% recommend and I will be back for an annual checkup!"

- Pardis

"I have a great experience with Georgia Retina staff they make me feel right at home when I walk through the doors."

- Michael

"Dr. Stallman is an excellent physician. The staff in this office give excellent service extrodinar. They are all very kind, professional, and genuinely concerned about your care. Love these folks!"

- Vale

"Very few doctors today display the confidence in their ability that Dr Mukkamala has. And does this without arrogance. He explains a complicated procedure and is sure that you understand when he finishes. I highly recommend him if you need this type of care."

- David

Novartis CRTH258C2302 Raven

Clinical Trial Team

Active Trials

Past Trials

Testimonials

What Our Patients Say

Retina Associates of Middle Georgia Joins Georgia Retina